These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 27656480)

  • 1. Comparative Effect of Insulin Sensitizers and Statin on Metabolic Profile and Ultrasonographical Score in Non Alcoholic Fatty Liver Disease.
    Rana H; Yadav SS; Reddy HD; Singhal S; Singh DK; Usman K
    J Clin Diagn Res; 2016 Aug; 10(8):OC19-23. PubMed ID: 27656480
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The effect of pioglitazone and metformin on liver function tests, insulin resistance, and liver fat content in nonalcoholic Fatty liver disease: a randomized double blinded clinical trial.
    Razavizade M; Jamali R; Arj A; Matini SM; Moraveji A; Taherkhani E
    Hepat Mon; 2013 May; 13(5):e9270. PubMed ID: 23930133
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Ultrasonography modifications of visceral and subcutaneous adipose tissue after pioglitazone or glibenclamide therapy combined with rosuvastatin in type 2 diabetic patients not well controlled by metformin.
    Maffioli P; Fogari E; D'Angelo A; Perrone T; Derosa G
    Eur J Gastroenterol Hepatol; 2013 Sep; 25(9):1113-22. PubMed ID: 23524525
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Ipragliflozin Additively Ameliorates Non-Alcoholic Fatty Liver Disease in Patients with Type 2 Diabetes Controlled with Metformin and Pioglitazone: A 24-Week Randomized Controlled Trial.
    Han E; Lee YH; Lee BW; Kang ES; Cha BS
    J Clin Med; 2020 Jan; 9(1):. PubMed ID: 31963648
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of silymarin plus vitamin E in patients with non-alcoholic fatty liver disease. A randomized clinical pilot study.
    Aller R; Izaola O; Gómez S; Tafur C; González G; Berroa E; Mora N; González JM; de Luis DA
    Eur Rev Med Pharmacol Sci; 2015 Aug; 19(16):3118-24. PubMed ID: 26367736
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Metformin prevents non-alcoholic fatty liver disease in rats: role of phospholipase A2/lysophosphatidylcholine lipoapoptosis pathway in hepatocytes].
    Huang Y; Fu JF; Shi HB; Liu LR
    Zhonghua Er Ke Za Zhi; 2011 Feb; 49(2):139-45. PubMed ID: 21426695
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Resistant nonalcoholic fatty liver disease amelioration with rosuvastatin and pioglitazone combination therapy in a patient with metabolic syndrome.
    Riche DM; Fleming JW; Malinowski SS; Black CA; Miller KH; Wofford MR
    Ann Pharmacother; 2014 Jan; 48(1):137-41. PubMed ID: 24259612
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Beneficial effects of lifestyle intervention in non-obese patients with non-alcoholic fatty liver disease.
    Wong VW; Wong GL; Chan RS; Shu SS; Cheung BH; Li LS; Chim AM; Chan CK; Leung JK; Chu WC; Woo J; Chan HL
    J Hepatol; 2018 Dec; 69(6):1349-1356. PubMed ID: 30142427
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Exenatide ameliorates experimental non-alcoholic fatty liver in rats via suppression of toll-like receptor 4/NFκB signaling: Comparison to metformin.
    Saad ZA; Khodeer DM; Zaitone SA; Ahmed AAM; Moustafa YM
    Life Sci; 2020 Jul; 253():117725. PubMed ID: 32348835
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of Pioglitazone and Metformin Efficacy against Glucocorticoid Induced Atherosclerosis and Hepatic Steatosis in Insulin Resistant Rats.
    Nayak IMN; Narendar K; M PA; Jamadar MG; Kumar VH
    J Clin Diagn Res; 2017 Jul; 11(7):FC06-FC10. PubMed ID: 28892924
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Research on the protection effect of pioglitazone for non-alcoholic fatty liver disease (NAFLD) in rats.
    Xu P; Zhang XG; Li YM; Yu CH; Xu L; Xu GY
    J Zhejiang Univ Sci B; 2006 Aug; 7(8):627-33. PubMed ID: 16845716
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Obesity and metabolic syndrome as risk factors for the development of non-alcoholic fatty liver disease as diagnosed by ultrasound.
    Petrović G; Bjelaković G; Benedeto-Stojanov D; Nagorni A; Brzački V; Marković-Živković B
    Vojnosanit Pregl; 2016 Oct; 73(10):910-20. PubMed ID: 29327896
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Improvements in clinical characteristics of patients with non-alcoholic fatty liver disease, after an intervention based on the Mediterranean lifestyle: a randomised controlled clinical trial.
    Katsagoni CN; Papatheodoridis GV; Ioannidou P; Deutsch M; Alexopoulou A; Papadopoulos N; Papageorgiou MV; Fragopoulou E; Kontogianni MD
    Br J Nutr; 2018 Jul; 120(2):164-175. PubMed ID: 29947322
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Increased serum concentration of ceramides in obese children with nonalcoholic fatty liver disease.
    Wasilewska N; Bobrus-Chociej A; Harasim-Symbor E; Tarasów E; Wojtkowska M; Chabowski A; Lebensztejn DM
    Lipids Health Dis; 2018 Sep; 17(1):216. PubMed ID: 30208901
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Metformin use in children with nonalcoholic fatty liver disease: an open-label, 24-month, observational pilot study.
    Nobili V; Manco M; Ciampalini P; Alisi A; Devito R; Bugianesi E; Marcellini M; Marchesini G
    Clin Ther; 2008 Jun; 30(6):1168-76. PubMed ID: 18640473
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Non-alcoholic fatty liver disease and non-alcoholic steatohepatitis in Albanian overweight children.
    Kodhelaj K; Resuli B; Petrela E; Malaj V; Jaze H
    Minerva Pediatr; 2014 Feb; 66(1):23-30. PubMed ID: 24608579
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy of
    Remya E; Goyal M; Varsakiya J
    Ayu; 2020; 41(2):98-106. PubMed ID: 34908794
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Management of Non-alcoholic Fatty Liver Disease and Steatohepatitis.
    Le TA; Loomba R
    J Clin Exp Hepatol; 2012 Jun; 2(2):156-73. PubMed ID: 25755424
    [TBL] [Abstract][Full Text] [Related]  

  • 19. MEASUREMENT OF CONTROLLED ATTENUATION PARAMETER: A SURROGATE MARKER OF HEPATIC STEATOSIS IN PATIENTS OF NONALCOHOLIC FATTY LIVER DISEASE ON LIFESTYLE MODIFICATION - A PROSPECTIVE FOLLOW-UP STUDY.
    Paul J; Venugopal RV; Peter L; Shetty KNK; Shetti MP
    Arq Gastroenterol; 2018; 55(1):7-13. PubMed ID: 29561981
    [TBL] [Abstract][Full Text] [Related]  

  • 20. LPSF/GQ-02 inhibits the development of hepatic steatosis and inflammation in a mouse model of non-alcoholic fatty liver disease (NAFLD).
    Soares e Silva AK; de Oliveira Cipriano Torres D; dos Santos Gomes FO; dos Santos Silva B; Lima Ribeiro E; Costa Oliveira A; dos Santos LA; de Lima Mdo C; Pitta Ida R; Peixoto CA
    PLoS One; 2015; 10(4):e0123787. PubMed ID: 25875942
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.